Wed, Apr 24th 2024
Canexis Pharma AG gains crucial Swissmedic licensing, setting the stage for advanced pharmaceutical cannabis production in Switzerland.
Canexis Pharma AG, a pioneering Swiss firm in pharmaceutical cannabis, announced today in a press release it has received crucial licenses from Swissmedic. This approval allows Canexis to commence production of high-quality CBD and THC-based pharmaceuticals for distribution in both Swiss and global markets.
Following an intense four-year development phase, production has begun at Canexis’ custom-designed facility in Schlattingen, Thurgau.
The plant, constructed to align with GMP standards, spans over 2,000 square meters, featuring state-of-the-art cleanrooms equipped with cutting-edge technology.
Inspection by Swissmedic has confirmed full compliance, paving the way for Canexis’ market entry later this year.
In just four years, we’ve built a pharmaceutical company from the ground up…We’re excited to transition from construction to contribution… and developing the pharmaceutical cannabis sector.
Sebastian Zeller, CEO of Canexis
The facility’s design and processes are optimised for cannabis extraction and processing, leveraging advanced European technology and knowledge-sharing with leading U.S. cannabis firms.
With the capacity to process up to 1,000 kg of cannabis, resulting in 100 kg of pure high-purity product daily, Canexis is well-positioned to supply between one to four million patients per day with pharmaceutical-grade cannabis products.
These products promise to enrich the medical cannabis market, currently dominated by bespoke prescription medicines, with a variety of standardised, high-purity pharmaceuticals.
English 
German 
French 
Spanish 
Arabic